NMD PHARMA NEUROMUSCULAR DISORDERS Logo (WIPO, 05/18/2018)
WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark NMD PHARMA NEUROMUSCULAR DISORDERS was filed as Figurative mark on 05/18/2018 at the World Intellectual Property Organization.
Logodesign (Wiener Klassifikation)
#Quadrilaterals #Letters presenting a special form of writing #Colours #Rhombs or squares standing on one of the corners thereof #Quadrilaterals with dark surfaces or parts of surfaces #Letters surmounted by a sign of disproportionate size #Series of letters in different dimensions #Three predominant colours
| Trademark form | Figurative mark |
| File reference | 1417454 |
| Countries | 
|
| Base trademark |
No. 017887341,
April 13, 2018
|
| Application date | May 18, 2018 |
| Expiration date | May 18, 2028 |
Trademark owner
c/o Capnova A/S,
Åbogade 15
DK
Åbogade 15
DK
Trademark representatives
Bredgade 30
1260 Copenhagen K
DK
goods and services
05
Preparations for pharmaceutical purposes, preparations for
medical purposes, chemical-pharmaceutical preparations,
diagnostic preparations for medical purposes, reagents for
medical purposes and for research, preparations for analysis
for medical and research purposes; pharmaceutical and
medical preparations for the treatment of rare and genetic
diseases; pharmaceutical and medical preparations for the
treatment of neurodegenerative diseases; pharmaceutical and
medical preparations for the treatment of neuromuscular
disorders; pharmaceutical and medical preparations that
strengthen neuromuscular transmission and muscle function in
patients with neuromuscular disorders, pharmaceutical and
medical preparations for acute hospital care
42
Scientific and technological services and research;
industrial analysis and research services; drug discovery
services; basic research and clinical research, hereunder
for medicine and vaccine development; development of medical
treatments related to rare and genetic diseases; development
of medical treatments related to neurodegenerative diseases;
development of medical treatments related to neuromuscular
disorders; development of medical treatments that strengthen
neuromuscular transmission and muscle function in patients
with neuromuscular disorders; development of medical
treatments for acute hospital care
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| July 15, 2022 | 2022/31 Gaz | Correction | |
| February 27, 2020 | 2020/9 Gaz | JP | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| January 6, 2020 | 2020/2 Gaz | KR | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| November 25, 2019 | 2019/49 Gaz | IN | Rejection |
| November 14, 2019 | 2019/47 Gaz | US | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| November 12, 2019 | 2019/48 Gaz | RAW: Limitation | |
| October 3, 2019 | 2019/43 Gaz | IL | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| October 3, 2019 | 2019/41 Gaz | RU | Rejection |
| July 19, 2019 | 2019/33 Gaz | SG | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| July 18, 2019 | 2019/30 Gaz | JP | Rejection |
| June 14, 2019 | 2019/32 Gaz | EM | RAW: Partial Ceasing Effect |
| June 5, 2019 | 2019/23 Gaz | MX | Rejection |
| May 9, 2019 | 2019/19 Gaz | KR | Rejection |
| February 26, 2019 | 2019/10 Gaz | RU | Rejection |
| February 21, 2019 | 2019/9 Gaz | IL | Rejection |
| February 18, 2019 | 2019/9 Gaz | CN | Rejection |
| December 6, 2018 | 2018/50 Gaz | SG | Rejection |
| September 22, 2018 | 2018/39 Gaz | US | Rejection |
| August 20, 2018 | 2018/36 Gaz | IN | Rejection |
| May 18, 2018 | 2018/30 Gaz | EM | Registration |
ID: 141417454